APLS   $40.23  135.40% Market Closed After Close 40.29 0.15%

Apellis Pharmaceuticals, Inc.
Total Cash 368.04M
totalCashPerShare 3.023
EBITDA -311.30M
Total Debt 474.51M
quickRatio 4.001
currentRatio 5.084
Total Revenue 628.79M
debtToEquity 179.516
Revenue/Share 5.15
ROA -0.21506001
ROE -1.09194
grossProfits
freeCashflow -336.11M
operatingCashflow -408.28M
earningsGrowth
revenueGrowth 1.103
grossMargins 0.36865002
ebitdaMargins -0.49508
operatingMargins -0.14745
profitMargins -0.52942
enterpriseValue 3.58B
forwardPE -56.52941
floatShares 82.01M
sharesOutstanding 124.39M
sharesShort 21.09M
sharesShortPriorMonth 15.28M
dateShortInterest
sharesPercentSharesOut 0.17%
heldPercentInsiders 0.14%
heldPercentInstitutions 0.98%
Short Ratio help_outline 6.81%
shortPercentOfFloat 0.24%
impliedSharesOutstanding
bookValue 1.627
Price To Book help_outline 17.72
earningsQuarterlyGrowth
netIncomeToCommon -332.89M
trailingEps -2.03%
forwardEps -0.51%
enterpriseToEbitda -11.51
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.29 4Q 2024
institutionsCount 382
lastUpdated Nov. 7, 2024, 2:44 a.m.